Ben Knox-Brown
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ben Knox-Brown has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- André Filipe Santos Amaral
National Heart and Lung Institute, Imperial College London, London, UK
12 shared publications James Potts
National Heart and Lung Institute, Imperial College London, London, UK
9 shared publications- Karl Peter Sylvester
Respiratory Physiology, Papworth Hospital NHS Foundation Trust, Cambridge, UK
8 shared publications Rune Nielsen
Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway
6 shared publications- Christer Janson
Department of Medical Sciences, Uppsala University, Uppsala, Sweden
5 shared publications Dhiraj Agarwal
Vadu Rural Health Program, KEM Hospital Pune Research Centre, Pune, Maharashtra, India
5 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Springer Nature in Discover Respiratory Health
- Vol. 1 (1) , 2
The impact of peak expiratory flow variability on FEV1 repeatability
Background: This study evaluated the impact of Peak Expiratory Flow (PEF) variability on Forced Expiratory Volume in one second (FEV 1 ) repeatability during spirometry and assessed the validity of the current Association for Respiratory Technology and Physiology (ARTP) repeatability threshold (40 L min −1 ). Methods: A retrospective observational study was performed at Royal Papworth Hospital NHS Foundation Trust using spirometry data from 4,913 patients (22,071 manoeuvres) in 2023. The manoeuvre with the highest PEF was used as the reference; PEF and FEV 1 differences were calculated for all remaining manoeuvres. Patients were stratified by obstruction status (FEV 1 /FVC < LLN vs. ≥ LLN). PEF variability was grouped into bands (< 40 to ≥ 200 L min −1 ). FEV 1 differences were compared across PEF groups using Mann-Whitney U and Friedman tests. Receiver Operating Characteristic (ROC) analysis was used to identify the PEF threshold predictive of clinically significant FEV 1 differences ( > ± 150 mL). We used multivariable logistic regression analysis to investigate the association of the derived threshold with having an FEV 1 difference > ± 150 mL. Results: Airflow obstruction was present in 31% of patients. Across all manoeuvres, the median PEF difference was 25 L min −1 and the median FEV 1 difference was 50 mL. 30% of manoeuvres exceeded the ARTP threshold, and these showed significantly greater FEV 1 variability (80 vs. 40 mL, p < 0.001). A progressive increase in FEV 1 difference occurred with rising PEF variability, most notably in obstructed patients. ROC analysis identified an optimal threshold of 44 L min −1 , with values above this conferring nearly threefold higher odds of an FEV 1 difference > ± 150 mL (OR 2.85; 95% CI 2.61–3.11). Conclusion: PEF variability is strongly associated with FEV 1 repeatability, particularly in obstructed patients. The optimal threshold identified (44 L min −1 ) closely aligns with the current ARTP criterion, supporting its validity. Larger PEF variability substantially increases the likelihood of clinically meaningful FEV 1 differences. Further work should examine implications for disease grading and clinical decisions.
- 29 October 2026
- Published by Springer Nature in Discover Respiratory Health
- Vol. 1 (1) , 2
Open AccessThe impact of peak expiratory flow variability on FEV1 repeatability
Background: This study evaluated the impact of Peak Expiratory Flow (PEF) variability on Forced Expiratory Volume in one second (FEV 1 ) repeatability during spirometry and assessed the validity of the current Association for Respiratory Technology and Physiology (ARTP) repeatability threshold (40 L min −1 ). Methods: A retrospective observational study was performed at Royal Papworth Hospital NHS Foundation Trust using spirometry data from 4,913 patients (22,071 manoeuvres) in 2023. The manoeuvre with the highest PEF was used as the reference; PEF and FEV 1 differences were calculated for all remaining manoeuvres. Patients were stratified by obstruction status (FEV 1 /FVC < LLN vs. ≥ LLN). PEF variability was grouped into bands (< 40 to ≥ 200 L min −1 ). FEV 1 differences were compared across PEF groups using Mann-Whitney U and Friedman tests. Receiver Operating Characteristic (ROC) analysis was used to identify the PEF threshold predictive of clinically significant FEV 1 differences ( > ± 150 mL). We used multivariable logistic regression analysis to investigate the association of the derived threshold with having an FEV 1 difference > ± 150 mL. Results: Airflow obstruction was present in 31% of patients. Across all manoeuvres, the median PEF difference was 25 L min −1 and the median FEV 1 difference was 50 mL. 30% of manoeuvres exceeded the ARTP threshold, and these showed significantly greater FEV 1 variability (80 vs. 40 mL, p < 0.001). A progressive increase in FEV 1 difference occurred with rising PEF variability, most notably in obstructed patients. ROC analysis identified an optimal threshold of 44 L min −1 , with values above this conferring nearly threefold higher odds of an FEV 1 difference > ± 150 mL (OR 2.85; 95% CI 2.61–3.11). Conclusion: PEF variability is strongly associated with FEV 1 repeatability, particularly in obstructed patients. The optimal threshold identified (44 L min −1 ) closely aligns with the current ARTP criterion, supporting its validity. Larger PEF variability substantially increases the likelihood of clinically meaningful FEV 1 differences. Further work should examine implications for disease grading and clinical decisions.
- Open Access
- 13 August 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
SpO 2 recovery time improves prognostic assessment in interstitial lung disease
Introduction: Six-minute walk test (6MWT) parameters assess prognosis in interstitial lung disease (ILD). While exercise-induced desaturation and six-minute walk distance (6MWD) are established predictors, the prognostic value of oxygen saturation (SpO 2 ) recovery time is less clear and is not included in current 6MWT risk models like distance-oxygen gender age physiology (DO-GAP) and oxygen flow rate, distance, dyspnoea and saturation (ODDS), Methods: 323 ILD patients undergoing 6MWT at Royal Papworth Hospital NHS Foundation Trust were included. SpO 2 recovery time was defined as the time taken for SpO 2 % to return within 2% of baseline following 6MWT. Associations with 1- and 2-year mortality or lung transplantation were assessed using ROC analysis, Kaplan–Meier curves, and Cox regression. Incremental prognostic value was evaluated by adding SpO 2 recovery time to DO-GAP and ODDS models using C-index, AIC, and likelihood ratio testing. Results: SpO 2 recovery demonstrated good discrimination for 1- and 2-year outcomes (AUC 0.75 and 0.73). Kaplan–Meier and pairwise analyses showed a graded association between recovery time and outcomes, with significant differences between 120 s, although separation was greatest for >120 s. In multivariable analysis, TLCO (HR 0.94, 95% CI 0.92–0.96, p120 s (HR 2.11, 95% CI 1.04–4.29, p=0.039) were independently associated with outcomes. Addition of SpO 2 recovery improved ODDS model performance (p120 s) independently predicted outcomes and improved existing developed risk models in ILD.
- 13 August 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Open AccessSpO 2 recovery time improves prognostic assessment in interstitial lung disease
Introduction: Six-minute walk test (6MWT) parameters assess prognosis in interstitial lung disease (ILD). While exercise-induced desaturation and six-minute walk distance (6MWD) are established predictors, the prognostic value of oxygen saturation (SpO 2 ) recovery time is less clear and is not included in current 6MWT risk models like distance-oxygen gender age physiology (DO-GAP) and oxygen flow rate, distance, dyspnoea and saturation (ODDS), Methods: 323 ILD patients undergoing 6MWT at Royal Papworth Hospital NHS Foundation Trust were included. SpO 2 recovery time was defined as the time taken for SpO 2 % to return within 2% of baseline following 6MWT. Associations with 1- and 2-year mortality or lung transplantation were assessed using ROC analysis, Kaplan–Meier curves, and Cox regression. Incremental prognostic value was evaluated by adding SpO 2 recovery time to DO-GAP and ODDS models using C-index, AIC, and likelihood ratio testing. Results: SpO 2 recovery demonstrated good discrimination for 1- and 2-year outcomes (AUC 0.75 and 0.73). Kaplan–Meier and pairwise analyses showed a graded association between recovery time and outcomes, with significant differences between 120 s, although separation was greatest for >120 s. In multivariable analysis, TLCO (HR 0.94, 95% CI 0.92–0.96, p120 s (HR 2.11, 95% CI 1.04–4.29, p=0.039) were independently associated with outcomes. Addition of SpO 2 recovery improved ODDS model performance (p120 s) independently predicted outcomes and improved existing developed risk models in ILD.
- Open Access
- 6 August 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Physiological quotients for discriminating mortality and respiratory outcomes: a UK biobank cohort study
Background: Spirometry is traditionally interpreted using reference-based metrics derived from equations such as those from the Global Lung Function Initiative (GLI). Physiological quotients, which express lung function relative to a lower physiological boundary, have been proposed as an alternative approach. We aimed to compare the prognostic performance of physiological quotients with conventional reference-based metrics including both the GLI 2012 ethnicity-specific and the GLI 2023 Global equations, in a large population-based cohort. Methods: We analysed data from 270 599 UK Biobank participants aged 40–69 years with baseline spirometry. Physiological quotients were calculated for FEV 1 , FVC, and FEV 1 /FVC using previously established first percentile boundaries. Associations with all-cause and cause-specific mortality, respiratory hospitalisation, respiratory symptoms, and self-reported respiratory diagnoses were examined using Cox proportional hazards and logistic regression models. Results: Over a median follow-up of 15.7 years, 26 197 (10%) participants died. Lower physiological quotients were consistently associated with adverse outcomes. Each 1- sd decrement in FEV 1 Q, FVCQ, and FEV 1 /FVCQ was associated with higher all-cause mortality (HRs 1.06–1.09), cardiovascular mortality (HRs 1.06–1.20), respiratory mortality (HRs 1.28–1.77), and respiratory hospitalisation (HRs 1.04–1.41). Discrimination for all-cause mortality was modest (C-statistics 0.64–0.65), moderate for cardiovascular mortality (0.72–0.73), and good for respiratory mortality (0.76–0.79). Discrimination of respiratory hospitalisation was modest but slightly higher for FEV 1 Q and FVCQ (0.65) than for percent predicted values and z-scores (0.61–0.62). Across mortality outcomes, discriminative performance was similar between physiological quotients, percent predicted values, and z-scores. Conclusion: Physiological quotients demonstrated prognostic performance comparable to conventional reference-based spirometric metrics for mortality outcomes, while showing modest advantages for respiratory morbidity.
- 6 August 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Open AccessPhysiological quotients for discriminating mortality and respiratory outcomes: a UK biobank cohort study
Background: Spirometry is traditionally interpreted using reference-based metrics derived from equations such as those from the Global Lung Function Initiative (GLI). Physiological quotients, which express lung function relative to a lower physiological boundary, have been proposed as an alternative approach. We aimed to compare the prognostic performance of physiological quotients with conventional reference-based metrics including both the GLI 2012 ethnicity-specific and the GLI 2023 Global equations, in a large population-based cohort. Methods: We analysed data from 270 599 UK Biobank participants aged 40–69 years with baseline spirometry. Physiological quotients were calculated for FEV 1 , FVC, and FEV 1 /FVC using previously established first percentile boundaries. Associations with all-cause and cause-specific mortality, respiratory hospitalisation, respiratory symptoms, and self-reported respiratory diagnoses were examined using Cox proportional hazards and logistic regression models. Results: Over a median follow-up of 15.7 years, 26 197 (10%) participants died. Lower physiological quotients were consistently associated with adverse outcomes. Each 1- sd decrement in FEV 1 Q, FVCQ, and FEV 1 /FVCQ was associated with higher all-cause mortality (HRs 1.06–1.09), cardiovascular mortality (HRs 1.06–1.20), respiratory mortality (HRs 1.28–1.77), and respiratory hospitalisation (HRs 1.04–1.41). Discrimination for all-cause mortality was modest (C-statistics 0.64–0.65), moderate for cardiovascular mortality (0.72–0.73), and good for respiratory mortality (0.76–0.79). Discrimination of respiratory hospitalisation was modest but slightly higher for FEV 1 Q and FVCQ (0.65) than for percent predicted values and z-scores (0.61–0.62). Across mortality outcomes, discriminative performance was similar between physiological quotients, percent predicted values, and z-scores. Conclusion: Physiological quotients demonstrated prognostic performance comparable to conventional reference-based spirometric metrics for mortality outcomes, while showing modest advantages for respiratory morbidity.
- 19 March 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (3) , 2502533
Redefining chronic bronchitis: short-term symptoms or long-term burden?
Extract Respiratory symptoms are an important component of a clinical history and are often linked to worse patient outcomes [1–4]. In general populations, there is considerable variation in the prevalence of chronic cough, chronic phlegm, dyspnoea and wheeze across the globe [5–7], which has been associated with accelerated lung function decline and lower quality of life [8, 9]. Despite evidence demonstrating the importance of respiratory symptoms for the diagnosis and prognostication of respiratory disease, inconsistency in choice of symptom questionnaires can make it difficult to compare findings across cohorts. This is increasingly true for the clustering of symptoms used to define the presence of chronic bronchitis. Shareable abstract Prevalence of chronic bronchitis is highly dependent on the definition used. Consensus in the community is required on the best tool for defining chronic bronchitis, and whether this should reflect short-term symptoms, long-term burden, or both. https://bit.ly/4pSG29V
- 19 March 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (3) , 2502533
Redefining chronic bronchitis: short-term symptoms or long-term burden?
Extract Respiratory symptoms are an important component of a clinical history and are often linked to worse patient outcomes [1–4]. In general populations, there is considerable variation in the prevalence of chronic cough, chronic phlegm, dyspnoea and wheeze across the globe [5–7], which has been associated with accelerated lung function decline and lower quality of life [8, 9]. Despite evidence demonstrating the importance of respiratory symptoms for the diagnosis and prognostication of respiratory disease, inconsistency in choice of symptom questionnaires can make it difficult to compare findings across cohorts. This is increasingly true for the clustering of symptoms used to define the presence of chronic bronchitis. Shareable abstract Prevalence of chronic bronchitis is highly dependent on the definition used. Consensus in the community is required on the best tool for defining chronic bronchitis, and whether this should reflect short-term symptoms, long-term burden, or both. https://bit.ly/4pSG29V
- Open Access
- 23 February 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e003657
Impact of breathing frequency on respiratory oscillometry measurements: a randomised cross-over and observational study of asthma patients
Introduction: The impact of breathing frequency on respiratory oscillometry measurements is unknown. We aimed to investigate the impact of different breathing frequencies in patients with asthma. Method: We recruited patients from the severe asthma clinic at Cambridge University Hospitals. Using a randomised-crossover design, participants performed the forced oscillation technique at three different breathing frequencies (15, 30, 40 bpm) in a randomised order for each participant. A metronome was used to ensure the correct breathing frequency. Analysis of variance (ANOVA) and Friedman tests were utilised to assess the significance of any differences across the breathing frequencies. We then leveraged cross-sectional data from asthma patients who performed respiratory oscillometry and investigated the determinants of self-selected breathing frequency using multivariable linear regression. Results: We recruited 59 patients. Mean age 54.1 years, 58% female, median forced expiratory volume in 1 s (FEV 1 )/FVC z-score −2.56 (−3.26 to −1.96). As breathing frequency increased from 15 bpm to 40 bpm, there was a significant reduction (−8.6%, p<0.001) in total airway resistance (Rrs at 5 Hz), which was not mediated by changes in tidal volume or flow rate. There was also a significant reduction (−14.9%, p<0.001) in Delta R5–R19, and an increase (+10.9%, p=0.081) in reactance (Xrs at 5 Hz). At higher breathing frequencies, 5% of study participants were reclassified as having respiratory oscillometry measurements within normal limits. Data from 796 asthma patients were extracted for the cross-sectional analysis. The median (range) self-selected breathing frequency was 16.55 bpm (8.0, 42.0). Demographic data and lung function explained 23.5% of the variation in breathing frequency. Conclusion: Higher breathing frequencies significantly reduce total Rrs . When performing respiratory oscillometry, breathing frequency should be controlled at approximately 15 bpm to reduce risk of misclassification.
- 23 February 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e003657
Open AccessImpact of breathing frequency on respiratory oscillometry measurements: a randomised cross-over and observational study of asthma patients
Introduction: The impact of breathing frequency on respiratory oscillometry measurements is unknown. We aimed to investigate the impact of different breathing frequencies in patients with asthma. Method: We recruited patients from the severe asthma clinic at Cambridge University Hospitals. Using a randomised-crossover design, participants performed the forced oscillation technique at three different breathing frequencies (15, 30, 40 bpm) in a randomised order for each participant. A metronome was used to ensure the correct breathing frequency. Analysis of variance (ANOVA) and Friedman tests were utilised to assess the significance of any differences across the breathing frequencies. We then leveraged cross-sectional data from asthma patients who performed respiratory oscillometry and investigated the determinants of self-selected breathing frequency using multivariable linear regression. Results: We recruited 59 patients. Mean age 54.1 years, 58% female, median forced expiratory volume in 1 s (FEV 1 )/FVC z-score −2.56 (−3.26 to −1.96). As breathing frequency increased from 15 bpm to 40 bpm, there was a significant reduction (−8.6%, p<0.001) in total airway resistance (Rrs at 5 Hz), which was not mediated by changes in tidal volume or flow rate. There was also a significant reduction (−14.9%, p<0.001) in Delta R5–R19, and an increase (+10.9%, p=0.081) in reactance (Xrs at 5 Hz). At higher breathing frequencies, 5% of study participants were reclassified as having respiratory oscillometry measurements within normal limits. Data from 796 asthma patients were extracted for the cross-sectional analysis. The median (range) self-selected breathing frequency was 16.55 bpm (8.0, 42.0). Demographic data and lung function explained 23.5% of the variation in breathing frequency. Conclusion: Higher breathing frequencies significantly reduce total Rrs . When performing respiratory oscillometry, breathing frequency should be controlled at approximately 15 bpm to reduce risk of misclassification.
- Open Access
- 22 January 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (1) , 2502204
Physiological quotients and mortality: redefining lung function interpretation beyond FEV 1
Background: Forced expiratory volume in 1 s quotient (FEV 1 Q) is a physiological quotient reflecting the distance a measured FEV 1 is from a 1st percentile (minimally survivable) value. We aimed to derive physiological quotients for other lung function measures and assess their association with all-cause mortality. Methods: We analysed data from adults referred for lung function testing at Cambridge University Hospital (CUH) and Royal Papworth Hospital (RPH) in the UK between 2016 and 2024. We investigated the stability of the 1st percentiles for FEV 1 , forced vital capacity (FVC), FEV 1 /FVC, diffusing capacity of the lung for carbon monoxide ( D LCO ), transfer coefficient of the lung for carbon monoxide ( K CO ), alveolar volume ( V A ) and total lung capacity (TLC) stratified by sex and age group by visualising the overlap of 95% confidence intervals. We calculated physiological quotients for each parameter (Q=measured value/1st percentile value) and investigated their association with all-cause mortality using Cox regression analysis. We used Harrell's C-index to compare discriminative performance. Results: We analysed data from 7717 CUH patients and 6054 RPH patients. At CUH, 51% were female compared with 45% at RPH. Mean± sd age was 57.9±14.9 years at CUH and 62.7±14.8 years at RPH. 1st percentile values were generally consistent across age groups but different for males and females for FEV 1 , FVC, V A and TLC. For FEV 1 /FVC, D LCO and K CO , 1st percentile values were generally stable across both age and sex. Mean± sd follow-up times were 5.8±2.6 years at CUH and 5.5±2.7 years at RPH, during which time 19% and 39% of patients died, respectively. Physiological quotients had higher Harrell's C-indexes, indicating better discrimination of survival than lung function expressed as raw units, z-scores and percent predicted. Conclusion: Physiological quotients have greater discriminative ability in the prediction of all-cause mortality than existing metrics, providing an alternative standard for lung function interpretation.
- 22 January 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (1) , 2502204
Open AccessPhysiological quotients and mortality: redefining lung function interpretation beyond FEV 1
Background: Forced expiratory volume in 1 s quotient (FEV 1 Q) is a physiological quotient reflecting the distance a measured FEV 1 is from a 1st percentile (minimally survivable) value. We aimed to derive physiological quotients for other lung function measures and assess their association with all-cause mortality. Methods: We analysed data from adults referred for lung function testing at Cambridge University Hospital (CUH) and Royal Papworth Hospital (RPH) in the UK between 2016 and 2024. We investigated the stability of the 1st percentiles for FEV 1 , forced vital capacity (FVC), FEV 1 /FVC, diffusing capacity of the lung for carbon monoxide ( D LCO ), transfer coefficient of the lung for carbon monoxide ( K CO ), alveolar volume ( V A ) and total lung capacity (TLC) stratified by sex and age group by visualising the overlap of 95% confidence intervals. We calculated physiological quotients for each parameter (Q=measured value/1st percentile value) and investigated their association with all-cause mortality using Cox regression analysis. We used Harrell's C-index to compare discriminative performance. Results: We analysed data from 7717 CUH patients and 6054 RPH patients. At CUH, 51% were female compared with 45% at RPH. Mean± sd age was 57.9±14.9 years at CUH and 62.7±14.8 years at RPH. 1st percentile values were generally consistent across age groups but different for males and females for FEV 1 , FVC, V A and TLC. For FEV 1 /FVC, D LCO and K CO , 1st percentile values were generally stable across both age and sex. Mean± sd follow-up times were 5.8±2.6 years at CUH and 5.5±2.7 years at RPH, during which time 19% and 39% of patients died, respectively. Physiological quotients had higher Harrell's C-indexes, indicating better discrimination of survival than lung function expressed as raw units, z-scores and percent predicted. Conclusion: Physiological quotients have greater discriminative ability in the prediction of all-cause mortality than existing metrics, providing an alternative standard for lung function interpretation.
- Open Access
- 13 January 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Lung capacity is a determinant of cardiovascular disease and myocardial infarction
Introduction: There is growing evidence suggesting that lung capacity is associated with risk of cardiometabolic disease. However, most studies rely on spirometric measures of lung capacity and self-reported cardiometabolic disease. We aimed to investigate the association of total lung capacity (TLC) with cardiometabolic disease defined using ICD-10 codes. Methods: Data from adult patients referred to Cambridge University Hospitals between 2016 and 2024 were used if spirometry, single breath gas transfer, and body plethysmography were performed in the same session. GLI reference equations were used to generate z-scores for lung function measures. ICD-10 codes for cardiovascular disease, hypertension, and diabetes were extracted from medical records. We used multi-level (mixed-effects) Cox regression analysis to investigate the association between lung function measurements and incident cardiometabolic disease. Results: 5628 patients were included, 51% were female, with a median age of 62 (IQR 50–70) years. 60% reported a smoking history. Mean follow-up time was 5.7 (SD 2.3) years, during which time 5% received a cardiovascular disease code, 7% a hypertension code, and 3% a diabetes code. A 1-unit increment in TLC z-score was associated with a 12% lower risk of cardiovascular disease (HR: 0.88, 95%CI 0.80–0.97) later in life. The same was seen for FVC (HR: 0.88, 95%CI 0.77–0.99) but not FEV 1 /FVC or DLCO. A larger TLC was also associated with lower risk of myocardial infarction. We found no association of lung function measures with incident hypertension or diabetes. Conclusion: Lung capacity is a determinant for cardiovascular disease and myocardial infarction, with larger lungs being protective. TLC and FVC should be considered by clinicians along with other factors, when evaluating a person’s risk of cardiovascular disease.
- 13 January 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Open AccessLung capacity is a determinant of cardiovascular disease and myocardial infarction
Introduction: There is growing evidence suggesting that lung capacity is associated with risk of cardiometabolic disease. However, most studies rely on spirometric measures of lung capacity and self-reported cardiometabolic disease. We aimed to investigate the association of total lung capacity (TLC) with cardiometabolic disease defined using ICD-10 codes. Methods: Data from adult patients referred to Cambridge University Hospitals between 2016 and 2024 were used if spirometry, single breath gas transfer, and body plethysmography were performed in the same session. GLI reference equations were used to generate z-scores for lung function measures. ICD-10 codes for cardiovascular disease, hypertension, and diabetes were extracted from medical records. We used multi-level (mixed-effects) Cox regression analysis to investigate the association between lung function measurements and incident cardiometabolic disease. Results: 5628 patients were included, 51% were female, with a median age of 62 (IQR 50–70) years. 60% reported a smoking history. Mean follow-up time was 5.7 (SD 2.3) years, during which time 5% received a cardiovascular disease code, 7% a hypertension code, and 3% a diabetes code. A 1-unit increment in TLC z-score was associated with a 12% lower risk of cardiovascular disease (HR: 0.88, 95%CI 0.80–0.97) later in life. The same was seen for FVC (HR: 0.88, 95%CI 0.77–0.99) but not FEV 1 /FVC or DLCO. A larger TLC was also associated with lower risk of myocardial infarction. We found no association of lung function measures with incident hypertension or diabetes. Conclusion: Lung capacity is a determinant for cardiovascular disease and myocardial infarction, with larger lungs being protective. TLC and FVC should be considered by clinicians along with other factors, when evaluating a person’s risk of cardiovascular disease.
- 1 December 2025
- Published by Wiley in Respirology
- Vol. 31 (3) , 228-229
Clarifying PRISm : The Complementary Role of Static Lung Volumes
See related article
- 1 December 2025
- Published by Wiley in Respirology
- Vol. 31 (3) , 228-229
Clarifying PRISm : The Complementary Role of Static Lung Volumes
See related article